Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 15 | 2020 | 1196 | 1.790 |
Why?
|
| Brain Ischemia | 12 | 2017 | 419 | 1.760 |
Why?
|
| Leukoaraiosis | 5 | 2015 | 45 | 1.720 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2015 | 117 | 1.340 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 1553 | 1.000 |
Why?
|
| Cost of Illness | 3 | 2015 | 162 | 0.970 |
Why?
|
| Intracranial Thrombosis | 1 | 2020 | 28 | 0.670 |
Why?
|
| Intracranial Embolism | 1 | 2020 | 39 | 0.650 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 66 | 0.650 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2020 | 86 | 0.630 |
Why?
|
| Cerebrum | 1 | 2015 | 16 | 0.480 |
Why?
|
| Brain | 9 | 2018 | 1552 | 0.470 |
Why?
|
| Brain Infarction | 2 | 2012 | 21 | 0.460 |
Why?
|
| White Matter | 3 | 2019 | 123 | 0.380 |
Why?
|
| Vision Disorders | 1 | 2012 | 64 | 0.370 |
Why?
|
| Lameness, Animal | 1 | 2010 | 9 | 0.340 |
Why?
|
| Horse Diseases | 1 | 2010 | 23 | 0.340 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 5463 | 0.320 |
Why?
|
| Middle Aged | 19 | 2020 | 17615 | 0.290 |
Why?
|
| Cerebral Hemorrhage | 2 | 2019 | 98 | 0.280 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2019 | 2176 | 0.280 |
Why?
|
| Aged | 19 | 2020 | 14449 | 0.270 |
Why?
|
| Male | 22 | 2020 | 29893 | 0.260 |
Why?
|
| Cerebral Infarction | 3 | 2016 | 83 | 0.260 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 834 | 0.230 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2016 | 153 | 0.220 |
Why?
|
| Retrospective Studies | 12 | 2019 | 6659 | 0.220 |
Why?
|
| Embolism | 2 | 2016 | 42 | 0.210 |
Why?
|
| Female | 21 | 2020 | 32883 | 0.210 |
Why?
|
| Humans | 24 | 2020 | 63449 | 0.190 |
Why?
|
| Echo-Planar Imaging | 1 | 2002 | 33 | 0.180 |
Why?
|
| Risk Factors | 10 | 2020 | 5354 | 0.170 |
Why?
|
| Atrial Remodeling | 1 | 2020 | 17 | 0.160 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 32 | 0.160 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 126 | 0.160 |
Why?
|
| Carotid Stenosis | 3 | 2008 | 105 | 0.160 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2020 | 44 | 0.160 |
Why?
|
| Heart Atria | 1 | 2020 | 137 | 0.150 |
Why?
|
| Antacids | 1 | 2019 | 14 | 0.150 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2018 | 9 | 0.150 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2017 | 8 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2016 | 36 | 0.130 |
Why?
|
| Adult | 8 | 2019 | 16826 | 0.120 |
Why?
|
| Aging | 1 | 2002 | 745 | 0.120 |
Why?
|
| Pneumonia | 1 | 2019 | 291 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2017 | 153 | 0.120 |
Why?
|
| Migraine Disorders | 1 | 2015 | 41 | 0.120 |
Why?
|
| Endarterectomy, Carotid | 2 | 2008 | 91 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 112 | 0.120 |
Why?
|
| Risk Assessment | 5 | 2020 | 2079 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 190 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2016 | 218 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 490 | 0.100 |
Why?
|
| Cerebrovascular Circulation | 2 | 2004 | 181 | 0.100 |
Why?
|
| United States | 2 | 2015 | 7843 | 0.090 |
Why?
|
| Diffusion | 2 | 2002 | 82 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2018 | 3293 | 0.090 |
Why?
|
| Retina | 1 | 2012 | 124 | 0.090 |
Why?
|
| Toe Phalanges | 1 | 2010 | 3 | 0.090 |
Why?
|
| Ligaments | 1 | 2010 | 12 | 0.080 |
Why?
|
| Tendons | 1 | 2010 | 25 | 0.080 |
Why?
|
| Horses | 1 | 2010 | 55 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2010 | 180 | 0.080 |
Why?
|
| Prognosis | 4 | 2020 | 1749 | 0.080 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 655 | 0.080 |
Why?
|
| Factor V | 1 | 2009 | 2 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2009 | 74 | 0.070 |
Why?
|
| Heterozygote | 1 | 2009 | 170 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2004 | 186 | 0.060 |
Why?
|
| Time Factors | 4 | 2016 | 3768 | 0.060 |
Why?
|
| Thrombosis | 1 | 2009 | 199 | 0.060 |
Why?
|
| Registries | 3 | 2016 | 888 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1094 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 313 | 0.060 |
Why?
|
| Cognition | 1 | 2008 | 484 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2016 | 583 | 0.050 |
Why?
|
| Prevalence | 1 | 2007 | 1380 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2007 | 495 | 0.050 |
Why?
|
| Intracranial Aneurysm | 1 | 2007 | 367 | 0.050 |
Why?
|
| Age Factors | 2 | 2016 | 1558 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 331 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2016 | 768 | 0.040 |
Why?
|
| Animals | 2 | 2010 | 20663 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 2570 | 0.040 |
Why?
|
| Acute Disease | 1 | 2002 | 671 | 0.040 |
Why?
|
| Radiography | 1 | 2002 | 550 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 1644 | 0.040 |
Why?
|
| Histamine H2 Antagonists | 1 | 2019 | 16 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 61 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 978 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 43 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 753 | 0.040 |
Why?
|
| Hematoma | 1 | 2018 | 80 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 5680 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 215 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 498 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 418 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2016 | 93 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 772 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 217 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2016 | 153 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1173 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 937 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 377 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1276 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 978 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 422 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1119 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1654 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 641 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 730 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 658 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2459 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 608 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2008 | 392 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 719 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 1207 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 2003 | 9 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2003 | 25 | 0.010 |
Why?
|
| Vasomotor System | 1 | 2003 | 22 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2003 | 137 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2003 | 193 | 0.010 |
Why?
|
| Contrast Media | 1 | 2004 | 426 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2003 | 250 | 0.010 |
Why?
|
| Mutation | 1 | 2009 | 2612 | 0.010 |
Why?
|
| Adolescent | 1 | 2007 | 6245 | 0.010 |
Why?
|